« Previous AbstractFrequency of aggregation substance and cytolysin genes among enterococcal endocarditis isolates    Next AbstractMolecular cloning and sequencing of thioesterase B cDNA and stimulation of expression of the thioesterase B gene associated with hormonal induction of peroxisome proliferation »

Evid Based Complement Alternat Med

Title:		BRM270 Inhibits the Proliferation of CD44 Positive Pancreatic Ductal Adenocarcinoma Cells via Downregulation of Sonic Hedgehog Signaling
Author(s):		Huynh DL; Koh H; Chandimali N; Zhang JJ; Kim N; Kang TY; Ghosh M; Gera M; Park YH; Kwon T; Jeong DK;
Address:		"Laboratory of Animal Genetic Engineering and Stem Cell Biology, Advanced Convergence Technology & Science, Jeju National University, Jeju 63243, Republic of Korea. Chongqing Key Laboratory of Forage and Herbivore, College of Animal Science and Technology, Southwest University, Chongqing 400715, China. Jeju Special Self-Governing Province Livestock Promotion Agency, 13 Chuksanmaeul-gil, Jeju 63078, Republic of Korea. Department of Biotechnology, Division of Research and Development, Lovely Professional University, Punjab 144411, India. BRM Institute, Seoul 01756, Republic of Korea. Primate Resource Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Jeongeup-si, Jeonbuk 56216, Republic of Korea"
Journal Title:		Evid Based Complement Alternat Med
Year:		2019
Volume:		20190224
Issue:
Page Number:		8620469 -
DOI:		10.1155/2019/8620469
ISSN/ISBN:		1741-427X (Print) 1741-4288 (Electronic) 1741-427X (Linking)
Abstract:		"Pancreatic cancer has a poor survival rate as compared to other types of cancer. Surface marker CD44 plays important role in epithelial-mesenchymal transition and cancer stem cell phenotype. Therefore, targeting CD44 positive pancreatic cancer cells might enhance therapies effectiveness. Our previous studies indicated the antitumorigenesis effect of BRM270 in osteosarcoma, lung cancer, and glioblastoma; however there is no evidence on BRM270 impacts on pancreatic cancer growth. In this study, we investigated the effect of BRM270 on the isolated CD44 positive pancreatic ductal adenocarcinoma cells (CD44(+) PDAC). Results showed that CD44 positive cells undergo apoptosis induced by BRM270. Moreover, BRM270 also inhibits stemness and metastasis traits in CD44(+) PDAC via Sonic hedgehog signaling pathway and SALL4 expression. In vivo study indicated that tumor growth derived from CD44(+) PDAC was suppressed as daily uptake by BRM270 5 mg/kg. These data suggest the alternative approach in antipancreatic tumorigenesis via herbal plants extract and selectively targeting CD44(+) PDAC cells in tumor"
Keywords:
Notes:		"PubMed-not-MEDLINEHuynh, Do Luong Koh, Hyebin Chandimali, Nisansala Zhang, Jiao Jiao Kim, Nameun Kang, Tae Yoon Ghosh, Mrinmoy Gera, Meeta Park, Yang-Ho Kwon, Taeho Jeong, Dong Kee eng 2019/05/03 Evid Based Complement Alternat Med. 2019 Feb 24; 2019:8620469. doi: 10.1155/2019/8620469. eCollection 2019"